• Sophia Genetics highlighted a new multi-year AstraZeneca agreement to launch two companion diagnostic programs covering solid tumors, blood cancers.
• Q2 2026 IFRS revenue USD 23.31 million, up 27% year-over-year; constant-currency revenue USD 22.86 million, up 25%.
• Q2 analysis volume 115,000, up 22% year-over-year; net dollar retention 117%; annualized revenue churn below 1%.
• Q2 adjusted EBITDA loss USD 8.83 million versus USD 12.04 million a year earlier; cash balance USD 107.7 million.
• FY 2025 IFRS revenue USD 77.27 million on 391,000 analyses; genomics represented more than 90% of annual revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.